Legacy AI grade · Sources dated 2026-07-25. Not expert reviewed. Coverage is limited to the listed sources. About the new summary workflow

Phellinus linteus for Liver Health

Verdict: Insufficient Evidence

Across 4 PubMed studies, the evidence for Phellinus linteus in Liver Health grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.

U ⚫ U Unverified Insufficient Evidence

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.44

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

U · Insufficient Evidence

Confidence

73%

Broadly consistent

Evidence level

Single small RCT

How strongly each layer supports this effect

lower = less supportive

L11 AI re-checkIndependent read

0.20

L2 PubMedPrimary literature

0.40

L1 ExamineGlobal benchmark

0.50

L3 MechanismPlausibility

0.50

L5 Clinical bodiesAuthoritative stance

0.50

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.44
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 無高階證據可裁決
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Styrylpyrones from Phellinus linteus Mycelia Alleviate Non-Alcoholic Fatty Liver in HFHF Diet-Fed Mice

PMID: 35624762 2022 Animal Study n = 9

Finding: Dose-dependent reduction of hepatic lipid and body weight; upregulated pgc-1a/sirt1/adiponectin, downregulated gck/srebp-1c (p<0.001)

Government

View on PubMed

Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma

PMID: 38240856 2024 Animal Study n = 12

Finding: PL exerted dose-dependent antitumor effect in vivo; modulated tumor-immune microenvironment via FAK (p<0.01)

View on PubMed

Inhibitory Effect of Styrylpyrone Extract of Phellinus linteus on Hepatic Steatosis in HepG2 Cells

PMID: 36835095 2023 In vitro

Finding: 27% inhibition of lipid accumulation at 500 ug/mL; SOD +73%, GPx +67%; activated SIRT1/AMPK/PGC1-a

🟠 Limited quality

View on PubMed

Efficacy of Phellinus linteus (sanghuang) extract for improving immune functions: Study protocol for a randomized, double-blinded, placebo-controlled pilot trial

PMID: 32011496 2020 RCT (double-blind)

Finding: Protocol only, no results reported; primary endpoints are immune markers, not hepatic outcomes

🟠 Limited quality

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Cautious

MESIMA - phellinus linteus mycelium capsule; Marketing Category: unapproved drug other; NDC: 53144-1001; Labeler: Yein Trading & Global Co., Ltd; Manufacturer: Han Kook Sin Yak Pharmaceutical Co., Ltd.; Marketing Start Date: 2012-12-29 source↗

L4d TW TFDA / 衛福部

Neutral

桑黃（Phellinus linteus）之菌絲體及以椴木栽培之子實體，得作為食品原料使用；惟不得宣稱具有療效（如抗癌、治療腫瘤等），違者依《食品安全衛生管理法》及《健康食品管理法》規定處辦。 source↗

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬4 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-liver-health-INT-phellinus-linteus-001 繁體中文版 →